Thermo Fisher Scientific Announces Launch of Lentivirus Production Solution Aimed to Produce High Titer Lentiviral Vectors

Overview:

GIBCO CTS LV-MAX Lentiviral Production System is a complete lentivirus production solution designed to produce high titer lentiviral vectors. This is the first optimized LV vector production system in suspension culture designed to meet USP <1043> standards. The system provides a smooth transition from discovery through clinical and commercial manufacturing. The LV-MAX lentiviral production system reduces the cost of viral production, simplifies researchers’ workflow, utilizes regulatory compliant reagents and provides a clear path toward commercialization.

With the launch of the CTS LV-MAX lentiviral production system, Thermo Fisher Scientific has enhanced its industry-leading cell and gene therapy portfolio, providing a complete solution for production of clinically relevant lentiviral vectors.

Key Applications:

High-titer lentiviral vector production in a scalable suspension culture system format for use in cell and gene therapy applications.

Features/Benefits:

• Cost effective: Reduces costs by more than 50 percent when compared to competitors.
• High titers: Greater than 1 x 108 TU/mL (unconcentrated).
• Suspension Cell Culture System: The cGMP-banked HEK293 cell line for LV production facilitates large scale production.
• Research Grade and CTS Options: Seamless transition from discovery to commercial production, with CTS products conforming to USP <1043> recommendations, with Drug Master File or Regulatory Support Files.

Web Site:

http://thermofisher.com/lvmax